Article Notes
- Hepatic failure
- Neurological disease
- High-neostigmine dose > 60 mcg/kg
- Metastatic solid tumour
- Female sex
- Less than 120 min between NMBD administration and extubation
- Aminosteroid NMBD
- BMI more than 35
- Absence of nurse anaesthetist (CRNA)
- Having an experienced surgeon
Case report from Yamaguchi, Japan describing a confirmed sugammadex anaphylaxis in a 50kg woman receiving 4mg/kg sugammadex.
Notably, follow-up skin prick testing strongly suggests #1 hypersensitivity to free sugammadex molecules, rather than the sugammadex-rocuronium complex, and #2 hypersensitivity appears to be dose-related.
Why is this important?
First, because it identifies new novel risk factors for residual neuromuscular block (experienced surgeon, non-CRNA anesthesia provider...) and secondly, because the subtext reveals the lengths our specialty goes to avoid simply monitoring using qualitative NMB monitoring (TOFR)!
What did they find?
Rudolph et al. created a REsidual neuromuscular block Prediction Score (REPS) using Massachusetts General PACU data, applying covariate analysis to identify 10 risk factors, some more surprising than others:
Be smart:
These risk factors might suggest patients who need more careful monitoring, but you will probably be better off just using qualitative monitoring routinely. The utility of REPS itself is only modest with NPV & PPVs of 85% each.
The other takeaway is that rNMB is still demonstratably common, occurring in 20% of this cohort!
While there is both utility and some interesting insights from the LAS VEGAS risk score research, it also seems to have largely confirmed that higher risk patients, having more invasive or major surgery, and those who misbehave intraoperatively are more likely to experience postoperative pulmonary complications...